Type 2 diabetes affects millions of people all around the world. According to recent reports, a new type of drug has been developed for type 2 diabetes. They are called the SGLT2 inhibitors or the sodium-glucose cotransporter 2.
This drug has been associated with reduced risk of heart failure and deaths caused due to the same in a study led from Karolinska Institute, as published in The BMJ.
Heart problems like cardiovascular diseases are very common complication that arises from type 2 diabetes. The new SGLT2 inhibitors help reduce blood glucose levels but studies have shown that they may also reduce the risk of cardiovascular diseases in patients with type 2 diabetes. The study, however, does not clearly say if they will be effective in a broader patient group.
The study was conducted by researchers at Karolinska Institute in Sweden, Statens Serum Institute in Denmark, and NTNU in Norway and the Swedish National Diabetes Register. The researchers studied data on drug use, diseases, cause of death, etc. in around 21,000 patients with type 2 diabetes who began treatment with SGLT2 inhibitors between April 2013 and December 2016. This data was then compared with the same subject size, that began with treatment for diabetes with a different drug, the DPP4 inhibitor.
It was found that the use of SGLT2 inhibitors was associated with a reduced risk of heart failure by 34% as compared to DPP4-inhibitor use, but not with major cardiovascular events. It was also found that it was linked to a 20% lower risk of death.
In another analysis, researchers studied the risks only when patients took the drug and found that it reduces instances of heart failure as well as other major cardiovascular events.
Source: Nigerian Healthcare Blog